FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, namely to therapy and pharmacology. A therapeutically efficient amount of the substance PM00104 or its pharmaceutically acceptable salt is introduced to a mammal, in particular a human being. PM00104 or its pharmaceutically acceptable salt is introduced in a combination with medications, representing antimyeloma medications.
EFFECT: invention makes it possible to improve treatment of multiple myeloma, which is achieved due to reduction of the active substance toxicity.
28 cl, 5 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
| PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR TREATING BLOOD CANCER | 2017 |
|
RU2721409C1 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| DOSING REGIMES OF MELFLUFEN FOR CANCER DISEASES | 2016 |
|
RU2734930C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
